New hope for rare blood disease: experimental drug shows promise in early trial

NCT ID NCT04617925

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times

Summary

This study tested a drug called belantamab mafodotin in 35 adults with AL amyloidosis, a rare disease where abnormal proteins build up in organs. Participants had already tried other treatments without success. The goal was to see if the drug could reduce the abnormal protein levels and control the disease. The study also monitored side effects to understand the drug's safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre hospitalier Universitaire de Limoges -

    Limoges, 87042, France

  • Fondazione I.R.C.C.S Policlinico "San Matteo"

    Pavia, 27100, Italy

  • General Hospital of Athens "Alexandra"

    Athens, 115 28, Greece

  • Royal Free Hospital - London,

    London, United Kingdom

  • UMC Utrecht

    Utrecht, 3584 CX, Netherlands

  • University Hospital Heidelberg

    Heidelberg, 69120, Germany

Conditions

Explore the condition pages connected to this study.